Marijuana, Spice 'herbal high', and early neural development: Implications for rescheduling and legalization

Drug Testing and Analysis

Volumn 5, Issue 1, 2013, Pages 27-45

  Psychoyos, Delphine ^a   Vinod, K Yaragudri ^b,c  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Legalization; Marijuana; Neural development; Pregnancy; Rescheduling; Spice; Synthetic cannabinoids

Indexed keywords

'SPICE'; ANIMAL MODEL; BRANDED PRODUCTS; CENTRAL NERVOUS SYSTEMS; LEGALIZATION; MARIJUANA; NEURAL DEVELOPMENT; PREGNANCY; RESCHEDULING; SYNTHETIC CANNABINOID;

OBSTETRICS;

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AM 2201; AM 694; CANNABINOID 1 RECEPTOR; CANNABIS; CP 47497 C8; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; EXCIPIENT; EXOCANNABINOID DERIVATIVE; ILLICIT DRUG; JWH 073; JWH 210; JWH 398; JWN 250; JZL 184; NABILONE; NABIXIMOLS; NAM; OXIRAN ACETATE; OXIRAN HEXANOATE; PSYCHOTROPIC AGENT; RCS 08; RCS 4; RCS 4 C4; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602; URB 602 CARBAMATE; WWL 70;

ANENCEPHALUS; ANTIDEPRESSANT ACTIVITY; BEHAVIOR DISORDER; BRAIN DEVELOPMENT; BRAIN REGION; CELL MIGRATION; CELL PROLIFERATION; DRUG POTENCY; HUMAN; MENTAL DISEASE; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; ONTOGENY; PREGNANT WOMAN; PRENATAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SPICE; SYNTHESIS; TRANQUILIZING ACTIVITY;

EID: 84872150019     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1390     Document Type: Review

References (214)

1. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Mental Health Findings. Center for Behavioral Health Statistics and Quality, NSDUH, Series H-39, HHS Publication No. SMA10-4609, 2010. Available at: http://www.oas.samhsa.gov/NSDUH/2k9NSDUH/MH/2k9MHResults.htm [20 April 2012].
2. Y. Gaoni, R. Mechoulam The isolation and structure of delta-1- tetrahydrocannabinol and other neutral cannabinoids from hashish. J. Am. Chem. Soc. 1971, 93, 217.
3. R.D. Harbison, B. Mantilla-Plata Prenatal toxicity, maternal distribution and placental transfer of tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 1972, 180, 1446.
4. J.S. Kennedy, W.J. Waddell Whole-body autoradiography of the pregnant mouse after administration of 14C-9-THC. Toxicol. Appl. Pharm. 1972, 22, 252.
5. D.E. Hutchings, B.R. Martin, Z. Gamagaris, N. Miller, T. Fico Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci. 1989, 44, 697.
6. Anencephaly. Wikipedia, Dr Almazi. Available at: http://en.wikipedia.org/wiki/Anencephaly [17 June 2012].
7. M.M. van Gelder, J. Reefhuis, A.R. Caton, M.M. Werler, C.M. Druschel, N. Roeleveld Maternal periconceptional illicit drug use and the risk of congenital malformations. Epidemiology 2008, 20, 60.
8. N.L. Day, G. Richardson Prenatal marijuana use: Epidemiology, methodological issues and infant outcome, in Clinics in Perinatology, (Ed: I.J. Chasnoff), WB Saunders: Philadelphia, 1991, pp. 77-92.
9. United Nations Office on Drugs and Crime. Synthetic cannabinoids in herbal products, 2011-06-06. Available at: http://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf [24 April 2012].
10. L. Fattore, W. Fratta Beyond THC: The new generation of cannabinoid designer drugs. Front. Behav. Neurosci. 2011, 5, 60.
11. K.A. Seely, J. Lapoint, J.H. Moran, L. Fattore Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuro-Psychoph. 2012 Apr 26. [Epub ahead of print].
12. K.A. Seely, P.L. Prather, L.P. James, J.H. Moran Marijuana-based drugs: Innovative therapeutics or designer drugs of abuse? Mol. Interv. 2011, 11, 36.
13. M. ElSohly Quarterly Report, Potency Monitoring Project, Report 100, December 16, 2007 thru March 15, 2008. National Institute on Drug Abuse, Contract Number N01DA-5-7746. Available at: http://www.infocenters.co.il/ada/multimedia/full-pdf/marijuana_potency_usa.pdf [21 April 2012].
14. Z. Mehmedic, S. Chandra, D. Slade, H. Denham, S. Foster, A.S. Patel, et al. Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J. Forensic Sci. 2010, 55, 1209.
15. S. Sirikantaramas, F. Taura, S. Morimoto, Y. Shoyama Recent advances in Cannabis sativa research: biosynthetic studies and its potential in biotechnology. Curr. Pharm. Biotechnol. 2007, 8, 237.
16. 1-tetrahydrocannabinolic acid by the biosynthetic enzyme secreted from transgenic Pichia pastoris. Biochem. Bioph. Res. Co. 2007, 361, 675.
17. S. Sirikantaramas, S. Morimoto, Y. Shoyama, Y. Ishikawa, Y. Wada, Y. Shoyama, et al. The gene controlling marijuana psychoactivity: Molecular cloning and heterologous expression of delta-1-tetrahydrocannabinolic acid synthase from Cannabis sativa L. J. Biol. Chem. 2004, 279, 39767.
18. T. Yamauchi, Y. Shoyama, H. Aramaki, T. Azuma, I. Nishioka Tetrahydrocannabinolic acid, a genuine substance of tetrahydrocannabinol. Chem. Pharm. Bull. 1967, 15, 1075.
19. R.G. Pertwee Ligands that target cannabinoid receptors in the brain: From THC to anandamide and beyond. Addict. Biol. 2008, 13, 147.
20. K. Mackie Signaling via CNS cannabinoid receptors. Mol. Cell. Endocrinol. 2008, 286, S60.
21. M. Kano, T. Ohno-Shosaku, Y. Hashimotodani, M. Uchigashima, M. Watanabe Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 2009, 89, 309.
22. N. Stella, P. Schweitzer, D. Piomelli A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997, 388, 773.
23. T. Sugiura, T. Kodaka, S. Nakane, T. Miyashita, S. Kondo, Y. Suhara, et al. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 1999, 274, 2794.
24. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946.
25. E.S. Onaivi Commentary: Functional neuronal CB2 cannabinoid receptors in the CNS. Curr. Neuropharmacol. 2011, 9, 205.
26. P. Pacher, S. Batkai, G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58, 389.
27. D.M. Lambert, C.J. Fowler The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. 2005, 48, 5059.
28. U. Pagotto, G. Marsicano, D. Cota, B. Lutz, R. Pasquali The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 2006, 27, 73.
29. M. Bouaboula, C. Poinot-Chazel, B. Bourrie, X. Canat, B. Calandra, M. Rinaldi-Carmona, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 1995, 312, 637.
30. T.L. Daigle, C.S. Kearn, K. Mackie Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling. Neuropharmacology 2008, 54, 36.
31. P. Derkinderen, E. Valjent, M. Toutant, J.C. Corvol, H. Enslen, C. Ledent, et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci. 2003, 23, 2371.
32. D. Braida, M. Pozzi, R. Cavallini, M. Sala Conditioned place preference induced by the cannabinoid agonist CP 55, 940: interaction with the opioid system. Neuroscience 2001, 104, 923.
33. G. Marsicano, S. Goodenough, K. Monory, H. Hermann, M. Eder, A. Cannich, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302, 84.
34. B.E. Alger Endocannabinoids and their implications for epilepsy. Epilepsy Curr. 2004, 4, 169.
35. T. Bisogno, F. Howell, G. Williams, A. Minassi, M.G. Cascio, A. Ligresti, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 2003, 163, 463.
36. T.P. Dinh, D. Carpenter, F.M. Leslie, T.F. Freund, I. Katona, S.L. Sensi, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. P. Natl Acad. Sci. USA 2002, 99, 10819.
37. W.R. Marrs, J.L. Blankman, E.A. Horne, A. Thomazeau, Y.H. Lin, J. Coy, et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat. Neurosci. 2010, 13, 951.
38. J.R. Savinainen, S.M. Saario, J.T. Laitinen The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol (Oxf.) 2012, 204, 267.
39. J. Liu, L. Wang, J. Harvey-White, B.X. Huang, H.Y. Kim, S. Luquet, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 2008, 54, 7.
40. B.F. Cravatt, A.H. Lichtman The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem. Phys. Lipids 2002, 121, 135.
41. N. Laaris, C.H. Good, C.R. Lupica Δ9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus. Neuropharmacology 2010, 59, 121.
42. A synaptic transmission in the hippocampus. J. Neurosci. 2000, 20, 2470.
43. I. Katona, B. Sperlágh, A. Sík, A. Käfalvi, E.S. Vizi, K. Mackie, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 1999, 19, 4544.
44. I. Katona, B. Sperlágh, Z. Maglóczky, E. Sántha, A. Köfalvi, S. Czirják, et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000, 100, 797.
45. National Institute on Drug Abuse, NIH. Publication Number 05-3859, October 2005. Research Report Series: Marijuana Abuse. Available at: http://www.virginia.edu/case/ATOD/RRMarijuana.pdf [17 May 2012].
46. U.S. Department of Justice Drug Enforcement Administration. Title 21 United States Code (USC) Controlled Substances Act. Pub. L. 91-513, 84 Stat. 1236, enacted October 27, 1970. Available at: http://www.deadiversion.usdoj.gov/21cfr/21usc/index.html [15 May 2012].
47. R. Kikura-Hanajiri, N. Uchiyama, Y. Goda Survey of current trends in the abuse of psychotropic substances and plants in Japan. Leg. Med. (Tokyo) 2011, 13, 109.
48. European Monitoring Centre for Drugs and Drug Addiction. Understanding the Spice Phenomenon. Available at: http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spice%20Thematic%20paper%20-%20final%20version.pdf [24 April 2012].
49. J.L. Wiley, J.A. Marusich, J.W. Huffman, R.L. Balster, B.F. Thomas Hijacking of Basic Research: The Case of Synthetic Cannabinoids. Research Report. Research Triangle Institute Press publication OP-0007-1111. Available at: http://www.rti.org/pubs/op-0007-1111-wiley.pdf [24 April 2012].
50. N. Uchiyama, R. Kikura-Hanajiri, J. Ogata, Y. Goda Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci. Int. 2010, 198, 31.
51. A. Makriyannis, H. Deng Cannabimimetic indole derivatives. WO Patent No. 01/28557 A1, 1-25 PCT/US00/28832, 2001. Available at: http://worldwide.espacenet.com/publicationDetails/biblio?CC=WO&NR=0128557&KC=&FT=E&locale=en_EP [26 April 2012].
52. L.S. Melvin, G.M. Milne, M.R. Johnson, B. Subramaniam, G.H. Wilken, A.C. Howlett Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: Studies of bicyclic cannabinoid analogs. Mol. Pharmacol. 1993, 44, 1008.
53. B.K. Atwood, D. Lee, A. Straiker, T.S. Widlanski, K. Mackie CP47, 497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur. J. Pharmacol. 2011, 659, 139.
54. J. Ammann, J.M. McLaren, D. Gerostamopoulos, J. Beyer Detection and quantification of new designer drugs in human blood: part 1 - synthetic cannabinoids. J. Anal Toxicol. 2012, 36, 372.
55. M.R. Compton, L.S. Melvin, B.R. Martin Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 1992, 260, 201.
56. H. Guhring, J. Schuster, M. Hamza, M. Ates, C.E. Kotalla, K. Brune HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur. J. Pharmacol. 2001, 429, 127.
57. K. Tomiyama, M. Funada Cytotoxicity of synthetic cannabinoids found in 'Spice' products: The role of cannabinoid receptors and the caspase cascade in the NG 108-15 cell line. Toxicol. Lett. 2011, 207, 12.
58. B.K. Atwood, J. Huffman, A. Straiker, K. Mackie JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Brit. J. Pharmacol. 2010, 160, 585.
59. F. Molina-Holgado, E. Pinteaux, L. Heenan, J.D. Moore, N.J. Rothwell, R.M. Gibson Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol. Cell. Neurosci. 2005, 28, 189.
60. W. Jiang, Y. Zhang, L. Xiao, J. Van Cleemput, S.P. Ji, G. Bal, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest. 2005, 115, 3104.
61. F. Molina-Holgado, A. Rubio-Araiz, D. García-Ovejero, R.J. Williams, J.D. Moore, A. Arévalo-Martín, et al. CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur. J. Neurosci. 2007, 25, 629.
62. J.W. Huffman, P.V. Szklennik, A. Almond, K. Bushell, D.E. Selley, H. He 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg. Med. Chem. Lett. 2005, 15, 4110.
63. A. Weissman, G.M. Milne, L.S. Melvin Jr. Cannabimimetic activity from CP-47, 497, a derivative of 3-phenylcyclohexanol. J. Pharmacol. Exp. Ther. 1982, 223, 516.
64. P.J. Little, D.R. Compton, M.R. Johnson, L.S. Melvin, B.R. Martin Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 1988, 247, 1046.
65. J.Y. Shim, W.J. Welsh, A.C. Howlett Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction. Biopolymers 2003, 71, 169.
66. J.L. Wiley, D.R. Compton, D. Dai, J.A. Lainton, M. Phillips, J.W. Huffman, et al. Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J. Pharmacol. Exp. Ther. 1998, 285, 995.
67. C.N. Chin, J.W. Murphy, J.W. Huffman, D.A. Kendall The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J. Pharmacol. Exp. Ther. 1999, 291, 837.
68. C. Coulter, M. Garnier, C. Moore Synthetic cannabinoids in oral fluid. J. Anal. Toxicol. 2011, 35, 424.
69. L.J. Poklis, D. Amira, L.E. Wise, J.M. Wiebelhaus, B.J. Haggerty, A. Poklis Detection and disposition of JWH-018 and JWH-073 in mice after exposure to "Magic Gold" smoke. Forensic Sci. Int. 2012, 220, 91.
70. 2 receptor binding. Drug Alcohol Depend. 2000, 60, 133.
71. I. Möller, A. Wintermeyer, K. Bender, M. Jübner, A. Thomas, O. Krug Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test. Anal. 2011, 3, 609.
72. J. Teske, J.P. Weller, A. Fieguth, T. Rothämel, Y. Schulz, H.D. Tröger Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J. Chrom. 2010, 878, 2659.
73. S. Beuck, I. Möller, A. Thomas, A. Klose, N. Schlörer, W. Schänzer, et al. Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing. Anal. Bioanal. Chem. 2011, 2, 493.
74. C.L. Moran, V.H. Le, K.C. Chimalakonda, A.L. Smedley, F.D. Lackey, S.N. Owen, et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal. Chem. 2011, 83, 4228.
75. S.L. Kacinko, A. Xu, J.W. Homan, M.M. McMullin, D.M. Warrington, B.K. Logan Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood. J. Anal. Toxicol. 2011, 35, 386.
76. J.E. Kuster, J.I. Stevenson, S.J. Ward, T.E. D'Ambra, D.A. Haycock Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. J. Pharmacol. Exp. Ther. 1993, 264, 1352.
77. C.C. Felder, K.E. Joyce, E.M. Briley, J. Mansouri, K. Mackie, O. Blond, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 1995, 48, 443.
78. R.E. Hampson, F. Miller, G. Palchik, S.A. Deadwyler Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: Implications for endocannabinoid control of hippocampal neural plasticity. Neuropharmacology 2011, 60, 944.
79. N. Uchiyama, R. Kikura-Hanajiri, Y. Goda Identification of a novel cannabimimetic phenylacetylindole, cannabipiperidiethanone, as a designer drug in a herbal product and its affinity for cannabinoid CB1 and CB receptors. Chem. Pharm. Bull.(Tokyo) 2011, 59, 1203.
80. R. Lindigkeit, A. Boehme, I. Eiserloh, M. Luebbecke, M. Wiggermann, L. Ernst, et al. Spice: A never ending story? Forensic Sci. Int. 2009, 191, 58.
81. V. Auwärter, S. Dresen, W. Weinmann, M. Müller, M. Pütz, N. Ferreirós Spice' and other herbal blends: Harmless incense or cannabinoid designer drugs? J. Mass Spectrom. 2009, 44, 832.
82. Office of Diversion Control US Department of Justice Drug Enforcement Administration. Drugs and Chemicals of Concern. HU-210. Available at: http://www.deadiversion.usdoj.gov/drugs_concern/spice/spice_hu210.htm [30 April 2012].
83. House of Representatives, 112th Congress. H.R.1254 [Report No. 112-295, Parts I and III] To Amend the Controlled Substances Act to Place Synthetic Drugs in Schedule I. Available from: http://www.gpo.gov/fdsys/pkg/BILLS-112hr1254ih/pdf/BILLS-112hr1254ih.pdf [26 April 2012].
84. Committee Reports, 112th Congress. House Report 112-295 - Part 2: Synthetic Drug Control Act of 2011, The Library of Congress-Thomas. Available at: http://thomas.loc.gov/cgi-bin/cpquery/2?&sid=cp112KGP4l&refer=&r_n=hr295p2.112&db_id=112&item=2&&sid=cp112KGP4l&r_n=hr295p2.112&dbname=cp112&hd_count=2&item=2&&sel=TOC_63972& [23 April 2012].
85. G. Duncan Emerging Substances of Abuse - K2/Spice (Synthetic Cannabinoids). Available at: http://www.slideshare.net/Guedde/spicek2-synthetic-cannabinoids-6988186 [23 April 2012].
86. National Conference of State Legislatures. Cannabinoids (a.k.a. "K2" / "Spice") Enactments. Available at: http://www.ncsl.org/issues-research/justice/synthetic-cannabinoids-enactments.aspx [23 April 2012].
87. Office of Diversion Control US Department of Justice Drug Enforcement Administration. Controlled Substances - Alphabetical Order. Available at: http://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf [29 April 2012].
88. United States Drug Enforcement Administration. Chemicals Used in "Spice" and "K2" Type Products Now Under Federal Control and Regulation. United States Drug Enforcement Administration, Publication Number: 202-307-79772011. Available at: http://www.justice.gov/dea/pubs/pressrel/pr030111.html [25 April 2012].
89. Thrive Chemical Research. Available at: http://www.thrivechem.com/o-2545-hydrochloride-7509-p.asp [26 April 2012].
90. B.R. Martin, J.L. Wiley, I. Beletskaya, L.J. Sim-Selley, F.L. Smith, W.L. Dewey, et al. Pharmacological characterization of novel water-soluble cannabinoids. J. Pharmacol. Exp. Ther. 2006, 318, 1230.
91. C.J. Hillard, S. Manna, M.J. Greenberg, R. DiCamelli, R.A. Ross, L.A. Stevenson Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 1999, 289, 1427.
92. H. Deng, A.N. Gifford, A.M. Zvonok, G. Cui, X. Li, P. Fan, et al. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. J. Med. Chem. 2005, 48, 6386.
93. A.R. King, A. Duranti, A. Tontini, S. Rivara, A. Rosengarth, J.R. Clapper, et al. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem. Biol. 2007, 14, 1357.
94. Y.C. Ho, H.J. Lee, L.W. Tung, Y.Y. Liao, S.Y. Fu, S.F. Teng, et al. Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. J. Neurosci. 2011, 31, 14600.
95. M. Szabo, M. Agostino, D.T. Malone, E. Yuriev, B. Capuano The design, synthesis and biological evaluation of novel URB602 analogues as potential monoacylglycerol lipase inhibitors. Bioorg. Med. Chem. Lett. 2011, 21, 6782.
96. S.M. Saario, O.M. Salo, T. Nevalainen, A. Poso, J.T. Laitinen, T. Järvinen, et al. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem. Biol. 2005, 12, 649.
97. J.L. Blankman, G.M. Simon, B.F. Cravatt A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14, 1347.
98. J.J. Burston, L.J. Sim-Selley, J.P. Harloe, A. Mahadevan, R.K. Razdan, D.E. Selley, et al. N-arachidonyl maleimide potentiates the pharmalocogical and biochemical effects of the endocannabinoid 2-arachidonylyglycerol through inhibition of monoacylglycerol lipase. J. Pharmacol. Exp. Ther. 2008, 327, 546.
99. J.Z. Long, W. Li, L. Booker, J.J. Burston, S.G. Kinsey, J.E. Schlosburg, et al. Selective blockade of 2-arachidonylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 2009, 5, 37.
100. B. Pan, W. Wang, J.Z. Long, D. Sun, C.J. Hillard, B.F. Cravatt, et al. Blockade of 2-arachidonylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1, 3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) enhances retrograde endocannabinoid signaling. J. Pharmacol. Exp. Ther. 2009, 331, 591.
101. J.A. Cisneros, E. Björklund, I. González-Gil, Y. Hu, A. Canales, F.J. Medrano, et al. Structure-activity relationship of a new Series of reversible dual monoacylglycerol lipase/fatty acid amide hydrolase inhibitors. J. Med. Chem. 2012, 55, 824.
102. A. Minkkilä, M.J. Myllymäki, S.M. Saario, J.A. Castillo-Melendez, A.M. Koskinen, C.J. Fowler, et al. The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur. J. Med. Chem. 2009, 44, 2994.
103. J.L. Blankman, M. Simon, B.F. Cravatt A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonylglycerol. Chem. Biol. 2007, 14, 1347.
104. W. Li, J.L. Blankman, B.F. Cravatt A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J. Am. Chem. Soc. 2007, 129, 9594.
105. W.R. Marrs, E.A. Horne, S. Ortega-Gutierrez, J.A. Cisneros, C. Xu, Y.H. Lin, et al. Dual inhibition of alpha/beta-hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons. J. Biol. Chem. 2011, 286, 28723.
106. R.E. Vann, D.M. Walentiny, J.J. Burston, K.M. Tobey, T.F. Gamage, J.L. Wiley Enhancement of the behavioral effects of endogenous and exogenous cannabinoid agonists by phenylmethyl sulfonyl fluoride. Neuropharmacology 2012, 62, 1019.
107. B. Koutek, G.D. Prestwich, A.C. Howlett, S.A. Chin, D. Salehani, N. Akhavan, et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. J. Biol. Chem. 1994, 269, 22937.
108. T. Bisogno, D. Melck, L. De Petrocellis, M.Y. Bobrov, N.M. Gretskaya, V.V. Bezuglov, et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Comm. 1998, 248, 515.
109. J.M. Keith, R. Apodaca, W. Xiao, M. Seierstad, K. Pattabiraman, J. Wu, et al. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg. Med. Chem. Lett. 2008, 18, 4838.
110. S.A. Moore, G.G. Nomikos, A.K. Dickason-Chesterfield, D.A. Schober, J.M. Schaus, B.P. Ying, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. P. Natl Acad. Sci. USA 2005, 102, 17852.
111. L. De Petrocellis, D. Melck, N. Ueda, S. Maurelli, Y. Kurahashi, S. Yamamoto, et al. Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase. Biochem. Biophys. Res. Commun. 1997, 231, 82.
112. D.G. Deutsch, R. Omeir, G. Arreaza, D. Salehani, G.D. Prestwich, Z. Huang, et al. Methyl arachidonyl fluorophosphate: A potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol. 1997, 53, 255.
113. T. Bisogno, D. Melck, M.Y. Bobrov, N.M. Gretskaya, V.V. Bezuglov, L. De Petrocellis, et al. N-acyl-dopamines: Novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 2000, 351, 817.
114. K.O. Jonsson, S. Vandevoorde, D.M. Lambert, G. Tiger, C.J. Fowler Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Brit. J. Pharmacol. 2001, 133, 1263.
115. K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, M.K. McKinney, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol. 2009, 16, 411.
116. K. Ahn, D.S. Johnson, L.R. Fitzgerald, M. Liimatta, A. Arendse, T. Stevenson, et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 2007, 46, 13019.
117. M. Mileni, D.S. Johnson, Z. Wang, D.S. Everdeen, M. Liimatta, B. Pabst, et al. Structure-guided inhibitor design for human FAAH by interspecies active site conversion. P. Natl Acad. Sci. USA 2008, 105, 12820.
118. S. Gattinoni, C. De Simone, S. Dallavalle, F. Fezza, R. Nannei, D. Amadio, et al. Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system. Chem. Med. Chem. 2010, 5, 357.
119. A. Caprioli, R. Coccurello, C. Rapino, S. Di Serio, M. Tommaso, M. Vertechy, et al. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models. J. Pharmacol. Exp. Ther. 2012, 342, 188.
120. S.D. Roughley, H. Browne, A.T. Macias, K. Benwell, T. Brooks, J. D'Allessandro, et al. Fatty acid amide hydrolase inhibitors. 3: Tetra-substituted azetidine ureas with in vivo activity. Bioorg. Med. Chem. Lett. 2012, 22, 901.
121. J.L. Croxford Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003, 17, 179.
122. S. Tambaro, M. Bortolato Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat. CNS Drug Discov. 2012, 7, 25.
123. D. Piomelli, G. Tarzia, A. Duranti, A. Tontini, M. Mor, T.R. Compton, et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006, 12, 21.
124. S. Patel, C.J. Hillard Role of endocannabinoid signaling in anxiety and depression. Curr. Top. Behav. Neurosci. 2009, 1, 347.
125. K.Y. Vinod, S. Xie, D. Psychoyos, B.L. Hungund, T.B. Cooper, S.M. Tejani-Butt Dysfunction in Fatty Acid amide hydrolase is associated with depressive-like behavior in wistar kyoto rats. PLoS One 2012, 7, e36743.
126. M.P. Barnes Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin. Pharmacother. 2006, 5, 607.
127. A. Curtis, I. Mitchell, S. Pavel, N. Ives, H. Rickards A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov. Disord. 2009, 24, 2254.
128. N.T. Spratt Localization of the prospective neural plate in the early chick blastoderm. J. Exp. Zool. 1952, 120, 109.
129. C.D. Stern Neural induction: old problem, new findings, yet more questions. Development 2005, 132, 2007.
130. L. Wittler, M. Kessel The acquisition of neural fate in the chick. Mech. Dev. 2004, 121, 1031.
131. B.L. Balinsky An Introduction to Embryology, WB Saunders Co., New York, 1975.
132. Carnegie Stages Comparison. University of South Wales. Available at: http://embryology.med.unsw.edu.au/OtherEmb/CStages.htm [29 May 2012].
133. 9-THC exposure. Open Neuropsychopharmacol. J. 2009, 2, 64.
134. J.G. Corbin, N. Gaiano, S.L. Juliano, S. Poluch, E. Stancik, T.F. Haydar Regulation of neural progenitor cell development in the nervous system. J. Neurochem. 2008, 106, 2272.
135. D. Acampora, P. Barone, A. Simeone Otx genes in corticogenesis and brain development. Cereb. Cortex 1999, 9, 533.
136. T. Hirata, P. Li, G.M. Lanuza, L.A. Cocas, M.M. Huntsman, J.G. Corbin Identification of distinct telencephalic progenitor pools for neuronal diversity in the amygdala. Nat. Neurosci. 2009, 12, 141.
137. D. Psychoyos, K.Y. Vinod, J. Cao, S. Xie, R.L. Hyson, B. Wlodarczyk, et al. Cannabinoid receptor 1 signaling in embryo neurodevelopment. Birth Defects Res. B Dev. Reprod. Toxicol. 2012, 95, 137.
138. B. Migliarini, O. Carnevali A novel role for the endocannabinoid system during zebrafish development. Mol. Cell. Endocrinol. 2009, 299, 172.
139. N.E. Buckley, S. Hansson, G. Harta, E. Mezey Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 1998, 82, 1131.
140. J. Begbie, P. Doherty, A. Graham Cannabinoid receptor, CB1, expression follows neuronal differentiation in the early chick embryo. J. Anat. 2004, 205, 213.
141. J. Christiansen, E. Coles, V. Robinson, A. Pasini, D.G. Wilkinson Screening from a subtracted embryonic chick hindbrain cDNA library: Identification of genes expressed during hindbrain, midbrain and cranial neural crest development. Mech. Dev. 2001, 102, 119.
142. I. Galve-Roperh, J. Palazuelos, T. Aguado, M. Guzman The endocannabinoid system and the regulation of neural development: Potential implications in psychiatric disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259, 371.
143. E. Fride, N. Gobshtis, H. Dahan, A. Weller, A. Giuffrida, S. Ben-Shabat The endocannabinoid system during development: Emphasis on perinatal events and delayed effects. Vitam. Horm. 2009, 81, 139.
144. P. Campolongo, V. Trezza, P. Ratano, M. Palmery, V. Cuomo Developmental consequences of perinatal cannabis exposure: Behavioral and neuroendocrine effects in adult rodents. Psychopharmacology 2011, 214, 5.
145. J. Fernandez-Ruiz, M. Gomez, M. Hernandez, R. de Miguel, J.A. Ramos Cannabinoids and gene expression during brain development. Neurotox. Res. 2004, 6, 389.
146. T. Harkany, M. Guzman, I. Galve-Roperh, P. Berghuis, L.A. Devi, K. Mackie The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol. Sci. 2007, 28, 83.
147. S. Anavi-Goffer, J. Mulder The polarised life of the endocannabinoid system in CNS development. Chembiochem 2009, 10, 1591.
148. T. Harkany, E. Keimpema, K. Barabas, J. Mulder Endocannabinoid functions controlling neuronal specification during brain development. Mol. Cell. Endocrinol. 2008, 286, S84.
149. E. Keimpema, K. Barabas, Y.M. Morozov, G. Tortoriello, M. Torii, G. Cameron, et al. Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding. J. Neurosci. 2010, 30, 13992.
150. F. Berrendero, N. Sepe, J.A. Ramos, V. Di Marzo, J.J. Fernandez-Ruiz Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse 1999, 33, 181.
151. A. Biegon, I.A. Kerman Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. Neuroimage 2001, 14, 1463.
152. S. Mato, E. Del Olmo, A. Pazos Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur. J. Neurosci. 2003, 17, 1747.
153. X. Wang, D. Dow-Edwards, E. Keller, Y.L. Hurd Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience 2003, 118, 681.
154. T. Aguado, K. Monory, J. Palazuelos, N. Stella, B. Cravatt, B. Lutz, et al. The endocannabinoid system drives neural progenitor proliferation FASEB J. 2005, 19, 1704.
155. J.J. Fernandez-Ruiz, F. Berrendero, M.L. Hernandez, J. Romero, J.A. Ramos Role of endocannabinoids in brain development. Life Sci. 1999, 65, 725.
156. T. Vitalis, J. Lainé, A. Simon, A. Roland, C. Leterrier, Z. Lenkei The type 1 cannabinoid receptor is highly expressed in embryonic cortical projection neurones and negatively regulates neurite growth in vitro. Eur. J. Neurosci. 2008, 28, 1705.
157. J. Mulder, T. Aguado, E. Keimpema, K. Barabás, C.J. Ballester Rosado, L. Nguyen, et al. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. P. Natl Acad. Sci. USA 2008, 105, 8760.
158. M. Hernández, F. Berrendero, I. Suárez, L. García-Gil, M. Cebeira, K. Mackie, et al. Cannabinoid CB(1) receptors colocalize with tyrosine hydroxylase in cultured fetal mesencephalic neurons and their activation increases the levels of this enzyme. Brain Res. 2000, 857, 56.
159. Y.M. Morozov, M. Torii, P. Rakic Origin, early commitment, migratory routes, and destination of cannabinoid type 1 receptor-containing interneurons. Cereb. Cortex 2009, 19, I78.
160. F. Berrendero, L. García-Gil, M.L. Hernández, J. Romero, M. Cebeira, R. de Miguel, et al. Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development 1998, 125, 3179.
161. O. Nilsson, S.O. Jacobsson, C.J. Fowler Cannabinoid CB1 receptor activation does not prevent the toxicity of glutamate towards embryonic chick telencephalon primary cultures. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2003, 136, 245.
162. C.S. Wu, J. Zhu, J. Wager-Miller, S. Wang, D. O'Leary, K. Monory, et al. Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur. J. Neurosci. 2010, 32, 693.
163. T. Aguado, J. Palazuelos, K. Monory, N. Stella, B. Cravatt, B. Lutz, et al. The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J. Neurosci. 2006, 26, 1551.
164. P. Berghuis, M.B. Dobszay, X. Wang, S. Spano, F. Ledda, K.M. Sousa, et al. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. P. Natl Acad. Sci. USA 2005, 102, 19115.
165. P. Berghuis, A.M. Rajnicek, Y.M. Morozov, R.A. Ross, J. Mulder, G.M. Urban, et al. Hard- wiring the brain: Endocannabinoids shape neuronal connectivity. Science 2007, 316, 1212.
166. H.J. Kim, J.J. Waataja, S.A. Thayer Cannabinoids inhibit network-driven synapse loss between hippocampal neurones in culture. J. Pharmacol. Exp. Ther. 2008, 325, 850.
167. M. Shen, S.A. Thayer Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 1998, 54, 459.
168. D. Kim, S.A. Thayer Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J. Neurosci. 2001, 21, RC146.
169. E.J. Williams, F.S. Walsh, P. Doherty The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J. Cell Biol. 2003, 160, 481.
170. S. Watson, D. Chambers, C. Hobbs, P. Doherty, A. Graham The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation. Mol. Cell. Neurosci. 2008, 38, 89.
171. F. Molina-Holgado, A. Amaro, M.I. Gonzalez, F.J. Alvarez, M.L. Leret Effect of maternal delta 9-tetrahydrocannabinol on developing serotonergic system. Eur. J. Pharmacol. 1996, 316, 39.
172. I. Suarez, G. Bodega, J. Fernandez-Ruiz, J.A. Ramos, M. Rubio, B. Fernandez Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal delta9-tetrahydrocannabinol exposure. Cerebellum 2004, 3, 66.
173. T.V. Persaud, A.C. Ellington Cannabis in early pregnancy. Lancet 1967, 2, 1306.
174. M.G. Jonega Effects of delta9-tetrahydrocannabinol on hamster fetuses. J. Toxicol. Environ. Health 1977, 2, 1031.
175. W.F. Geber, L.C. Schramm Effect of marihuana extract on fetal hamsters and rabbits. Toxicol. Appl. Pharmacol. 1969, 14, 276.
176. B. Mantilla-Plata, C.L. Clewe, H.D. Harbison 9-tetrahydrocannabinol-induced changes in prenatal growth and development of animals. Toxicol. Appl. Pharmacol. 1975, 33, 333.
177. H. Rosenkrantz Effects of cannabis on fetal development of rodents. Adv. Biosc. 1978, 22, 479.
178. D. Psychoyos, B. Hungund, T. Cooper, R.H. Finnell A cannabinoid analogue of Delta9-tetrahydrocannabinol disrupts neural development in chick. Birth Defects Res. B Dev. Reprod. Toxicol. 2008, 83, 477.
179. H. Wang, H. Xie, S.K. Dey Endocannabinoid signaling directs periimplantation Events. AAPS J. 2006, 8, E425.
180. B. Park, J.M. McPartland, M. Glass Cannabis, cannabinoids and reproduction. Prostaglandins Leukot. Essent. Fatty Acids 2004, 70, 189.
181. P.A. Fried, J.E. Makin Neonatal behavioral correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. Neurotoxicol. Teratol. 1987, 9, 1.
182. G.A. Richardson, N.L. Day, L. Goldschmidt Prenatal alcohol, marijuana, and tobacco use: Infant mental and motor development. Neurotoxicol. Teratol. 1995, 17, 479.
183. H. El Marroun, J.J. Hudziak H. Tiemeier, H. Creemers, E.A. Steegers, V.W. Jaddoe, et al. Intrauterine cannabis exposure leads to more aggressive behavior and attention problems in 18-month-old girls. Drug Alcohol Depend. 1990, 118, 470.
184. P.A. Fried, B. Watkinson Cognitive development: memory and verbal outcome measures were negatively associated with prenatal marijuana use 36- and 48-month neurobehavioural follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol. J. Dev. Behav. Pediatr. 1990, 11, 49.
185. L. Goldschmidt, G.A. Richardson, J. Willford, N.L. Day Prenatal marijuana exposure and intelligence test performance at age 6. J. Am. Acad. Child Adolesc. Psychiatry 2008, 47, 254.
186. M.T. Stein, A. Drahota, D.A. Chavira Ian: a 7-year old with prenatal drug exposure and early exposure to family violence. J. Dev. Behav. Pediatr. 2008, 29, 512.
187. L. Goldschmidt, G.A. Richardson, M.D. Cornelius, N.L. Day Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol. Teratol. 2004, 26, 521.
188. G.A. Richardson, C. Ryan, J. Willford, N.L. Day, L. Goldschmidt Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol. Teratol. 2002, 24, 309.
189. J.S. Noland, L.T. Singer, E.J. Short, S. Minnes, R.E. Arendt, H.L. Kirchner, et al. Prenatal drug exposure and selective attention in preschoolers. Neurotoxicol. Teratol. 2005, 27, 429.
190. K.A. Gray, N.L. Day, S. Leech, G.A. Richardson Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. Neurotoxicol. Teratol. 2005, 27, 439.
191. A.M. Smith, P.A. Fried, M.J. Hogan, I. Cameron Effects of prenatal marijuana on response inhibition: an fMRI study of young adults. Neurotoxicol. Teratol. 2004, 26, 533.
192. A.C. Huizink, E.J.H. Mulder Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. Neurosci. Biobehav. Rev. 2006, 30, 24.
193. X. Wang, D. Dow-Edwards, V. Anderson, H. Minkoff, Y.L. Hurd In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol. Psychiatry 2004, 56, 909.
194. M.A. Spano, M. Ellgren, X. Wang, Y.L. Hurd Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood. Biol. Psychiatry 2007, 61, 554.
195. 1 receptor agonist WIN 55, 212-2 causes learning disruption associated with impaired cortical NMDA receptor function and emotional reactivity changes in rat offspring. Cereb. Cortex 2005, 15, 2013.
196. G. Mereu, M. Fà, L. Ferraro, T. Antonelli, M. Tattoli, V. Ghiglieri, et al. Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. P. Natl Acad. Sci. USA 2003, 100, 4915.
197. P. Campolongo, V. Trezza, T. Cassano, S. Gaetani, M.G. Morgese, M. Ubaldi, et al. Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats. Addict. Biol. 2007, 12, 485.
198. V. Trezza, P. Campolongo, T. Cassano, T. Macheda, P. Dipasquale, M.R. Carratù, et al. Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: A longitudinal behavioral study in Wistar rats. Psychopharmacology (Berl) 2008, 198, 529.
199. F. Rodriguez de Fonseca, M. Cebeira, J.J. Fernandez-Ruiz, M. Navarro, J.A. Ramos Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurones. Neuroscience 1991, 43, 713.
200. A. Bonnin, R. de Miguel, M.L. Hernandez, J.A. Ramos, J.J. Fernandez-Ruiz The prenatal exposure to delta 9-tetrahydrocannabinol affects the gene expression and the activity of tyrosine hydroxylase during early brain development. Life Sci. 1995, 56, 2177.
201. A. Bonnin, R. de Miguel, J.G. Castro, J.A. Ramos, J.J. Fernandez-Ruiz Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurones in rat brain. J. Mol. Neurosci. 1996, 7, 291.
202. G. Vela, S. Martin, L. Garcia-Gil, J.A. Crespo, M. Ruiz-Gayo, J.J. Fernández-Ruiz, et al. Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavioural and changes regional binding to central mu opioid receptors in adult offspring female rats. Brain Res. 1998, 807, 101.
203. J. Manzanares, J. Corchero, J. Romero, J.J. Fernandez-Ruiz, J.A. Ramos, J.A. Fuentes Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 1999, 20, 287.
204. A. Perez-Rosado, J. Manzanares, J. Fernandez-Ruiz, J.A. Ramos Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: Sex-dependent differences. Brain Res. Dev. Brain Res. 2000, 120, 77.
205. 1 cannabinoid receptors increase neuronal precursor proliferation through AKT/Glycogen synthase kinase-3β/β-Catenin signaling. J. Biol. Chem. 2010, 285, 10098.
206. C. Olenik, D.K. Meyer Development of proenkephalin gene expression in rat neocortex: A non-radioactive in situ hybridization study. Brain Res. Mol. Brain Res. 1997, 44, 83.
207. M.V. Sullivan, C.R. Hamilton Memory establishment via the anterior commissure of monkeys. Physiol. Behav. 1973, 11, 873.
208. M.S. Golub, E.N. Sassenrath, C.F. Chapman Regulation of visual attention in offspring of female monkeys treated chronically with D-9-tetrahydrocannabinol. Dev. Psychobiol. 1981, 14, 507.
209. A.C. Huizink, E.J. Mulder Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioural and cognitive functioning in human offspring. Neurosci. Biobehav. Rev. 2006, 30, 24.
210. M. Ashtari, K. Cervellione, J. Cottone, B.A. Ardekani, S. Kumra Diffusion abnormalities in adolescents and young adults with a history of heavy cannabis use. J. Psychiatr. Res. 2009, 43, 189.
211. L. Arseneault, M. Cannon, R. Poulton, R. Murray, A. Caspi, T.E. Moffitt Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br. Med. J. 2002, 325, 1212.
212. G.C. Patton, C. Coffey, J.B. Carlin, L. Degenhardt, M. Lynskey, W. Hall Cannabis use and mental health in young people: cohort study. Br. Med. J. 2002, 325, 1195.
213. California Senate Bill 420 (HS 11362.7) on Medical Marijuana Implementation. Available at: http://info.sen.ca.gov/pub/03-04/bill/sen/sb_0401-0450/sb_420_bill_20031012_chaptered.html [16 May 2012].
214. The National Organization for the Reform of Marijuana Laws (NORML), updated 2008. Available at: http://norml.org/ [15 May 2012].